SG
CEROW

StoneX Group’s CERo Therapeutics Warrants CEROW Stock Holding History

StoneX Group’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,250
Closed -$911 – 479
2023
Q1 		$911 Buy
30,250
+200
+0.7% +$9 ﹤0.01% 429
2022
Q4 		$1.29K Buy
+30,050
New +$1.58K ﹤0.01% 555

Other funds holding CEROW

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

StoneX Group's CEROW Position: Q2 2023 in Review

StoneX Group sold out of CERo Therapeutics Warrants (CEROW) in Q2 2023, closing a stake of 30,250 shares — an estimated $911 sold.

StoneX Group first reported a position in CEROW in Q4 2022 and held it in 2 quarters. The position peaked at $1.29K in Q4 2022. 43 funds tracked by Wall St. Rank hold CEROW as of Q2 2023.

  • StoneX Group reported no remaining CERo Therapeutics Warrants position as of Q2 2023 after selling out during the quarter.
  • StoneX Group sold 30,250 CERo Therapeutics Warrants shares in Q2 2023, an estimated $911.
  • StoneX Group first reported a position in CERo Therapeutics Warrants in Q4 2022 and held it in 2 quarters.
  • StoneX Group's CERo Therapeutics Warrants position peaked at $1.29K in Q4 2022.
  • 43 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q2 2023.

Based on StoneX Group's 13F filing for Q2 2023, filed 14 Aug 2023.